CHANGES IN NEUTROPENIA OUTCOMES FOLLOWING IMPLEMENTATION OF THE CLOZAPINE RISK EVALUATION AND MITIGATION STRATEGY UPDATE

被引：0
|
作者：
Chang, J. [1 ]
Taylor, K. [1 ]
Wei, Y. [1 ]
Huang, T. Y. [1 ]
机构：
[1] Komodo Hlth, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH16
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [1] Changes in Neutropenia Outcomes after the 2019 Clozapine Risk Evaluation and Mitigation Strategy Update
    Huang, Ting-Ying
    Chang, Jana
    Taylor, Kenneth
    Wei, Yuqin
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 58 - 59
  • [2] Risk Evaluation and Mitigation Strategy for Clozapine
    Cetin, Mesut
    Sayar, Gokben Hizli
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (01): : 1 - 6
  • [3] CLOZAPINE AND AGRANULOCYTOSIS: IMPACT OF THE RISK EVALUATION AND MITIGATION STRATEGY PROGRAM
    Borrelli, E. P.
    Lee, E. Y.
    Descoteaux, A. M.
    Caffrey, A. R.
    VALUE IN HEALTH, 2018, 21 : S180 - S180
  • [4] Optimizing Outcomes in Clozapine Rechallenge Following Neutropenia: A Cohort Analysis
    Meyer, Nicholas
    Gee, Siobhan
    Whiskey, Eromona
    Taylor, David
    Mijovic, Aleksandar
    Gaughran, Fiona
    Shergill, Sukhi
    MacCabe, James H.
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (11) : E1410 - E1416
  • [5] Changes in Thiazolidinedione Utilization and Outcomes Following Safety Warning and Risk Evaluation & Mitigation Strategies (REMS) in Taiwan
    Hsu, Jason C.
    Ross-Degnan, Dennis
    Cheng, Ching-Lan
    Wagner, Anita K.
    Zhang, Fang
    Yang, Yea-Huei Kao
    Liu, Li-Ling
    Tai, Hsueh-Yung
    Chen, Ke-Hsin
    Yang, Po-Wen
    Juan, Yi-Chen
    Lu, Christine Y.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 107 - 107
  • [6] Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy
    Bartelson, Becki Bucher
    Le Lait, M. Claire
    Green, Jody L.
    Cepeda, M. Soledad
    Coplan, Paul M.
    Maziere, Jean-Yves
    Wedin, Gregory P.
    Dart, Richard C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 (09) : 1061 - 1070
  • [7] Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy
    Wong, Hui-Lee
    Zhang, Rongmei
    Lufkin, Bradley
    Feng, Yuhui
    Lo, An-Chi
    Ngaiza, Manzi
    Wernecke, Michael
    Ryan, Qin
    Vega, Amarilys
    MaCurdy, Thomas E. E.
    Kelman, Jeffrey A. A.
    Graham, David J. J.
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (01) : 29 - 39
  • [8] Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy
    Hui-Lee Wong
    Rongmei Zhang
    Bradley Lufkin
    Yuhui Feng
    An-Chi Lo
    Manzi Ngaiza
    Michael Wernecke
    Qin Ryan
    Amarilys Vega
    Thomas E. MaCurdy
    Jeffrey A. Kelman
    David J. Graham
    Drugs & Therapy Perspectives, 2023, 39 : 29 - 39
  • [9] An Update on Risk Evaluation and Mitigation Strategies in Transplantation
    Gabardi, S.
    Halloran, P. F.
    Friedewald, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (01) : 257 - 258
  • [10] Changes in Mortality Involving Extended-Release and Long-Acting Opioids After Implementation of a Risk Evaluation and Mitigation Strategy
    Black, Joshua C.
    Bau, Gabrielle E.
    Rosen, Travis
    Cepeda, M. Soledad
    Wedin, Gregory P.
    Green, Jody L.
    Dart, Richard C.
    PAIN MEDICINE, 2020, 21 (01) : 92 - 100
12345